ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.
Think this is wrong? This is an automated estimate — request a human review or correction.
Lyell Immunopharma, Inc.
Company
Overview
Lyell Immunopharma, Inc. is a operating registered in SOUTH SAN FRANCISCO, United States. With reported revenue of 36K USD in 2025. Its TraceComp score of 53 (C) indicates elevated risk requiring further due diligence.
Company Information
- Registration Number
- 0001806952
- Legal Form
- Company
- Activity
- Pharmaceutical Preparations
- Address
- South-San-Francisco
Financial Profile
Latest filed accounts: FY 2025
Multi-year financials & ratios
1 year of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 97 publications · 10,397 citations · h-index 32 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (56%) · Immunology and Microbiology (24%) · Biochemistry, Genetics and Molecular Biology (18%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Net loss reported in FY 2025
Similar Companies
Data Sources & Freshness
Data sourced from: official public registries. Profile completeness: 70%.